High Dose Versus Low Dose Syngeneic Hepatocyte Transplantation in <i>Pex1</i>-G844D NMRI Mouse Model is Safe but Does Not Achieve Long Term Engraftment

• Main Authors: Tanguy Demaret, Jonathan Evraerts, Joachim Ravau, Martin Roumain, Giulio G. Muccioli, Mustapha Najimi, Etienne M. Sokal
• Format: Article
• Language: English
• Published: MDPI AG 2021-12-01
• Series: Cells
• Subjects: peroxisome biogenesis disorder; Zellweger spectrum disorder; oxysterols; mouse model; PEX1 p.Gly843Asp; PEX1 c.2528G&gt
• Online Access: https://www.mdpi.com/2073-4409/10/1/40

Genetic alterations in <i>PEX</i> genes lead to peroxisome biogenesis disorder. In humans, they are associated with Zellweger spectrum disorders (ZSD). No validated treatment has been shown to modify the dismal natural history of ZSD. Liver transplantation (LT) improved clinical and biochemical outcomes in mild ZSD patients. Hepatocyte transplantation (HT), developed to overcome LT limitations, was performed in a mild ZSD 4-year-old child with encouraging short-term results. Here, we evaluated low dose (12.5 million hepatocytes/kg) and high dose (50 million hepatocytes/kg) syngeneic male HT via intrasplenic infusion in the <i>Pex1</i>-G844D NMRI mouse model which recapitulates a mild ZSD phenotype. HT was feasible and safe in growth retarded ZSD mice. Clinical (weight and food intake) and biochemical parameters (very long-chain fatty acids, abnormal bile acids, etc.) were in accordance with ZSD phenotype but they were not robustly modified by HT. As expected, one third of the infused cells were detected in the liver 24 h post-HT. No liver nor spleen microchimerism was detected after 7, 14 and 30 days. Future optimizations are required to improve hepatocyte engraftment in <i>Pex1</i>-G844D NMRI mouse liver. The mouse model exhibited the robustness required for ZSD liver-targeted therapies evaluation.